Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Aug 11, 2026

Jupiter Neurosciences, Inc. (JUNS)

A forensic read on Jupiter Neurosciences, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

F · Poor — capital at risk

Forensic grade

Grey Zone

Financial health

6.8

Distress distance

Clean

Earnings quality

Forensic signals

-0.3

P / E (ttm)

$288M

Market cap

0.00%

Dividend yield

0.0%

Revenue growth

This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.

Jupiter Neurosciences, Inc. earns an F (Poor — capital at risk) forensic quality grade, and its balance-sheet distress test reads 6.8, placing it in the Grey zone. 3 forensic signals were flagged in its latest SEC filings, led by share-count dilution.

What the filings flag

+20.3%/yr

FY2024–FY2025

Share-count dilution. Diluted share count changed +20% over the last 1 year to FY2025 (+20.3%/yr). The count is growing: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~20.3% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2024 has been diluted ~17%.

n/m (sign flip)

FY2024→FY2025

Accruals ratio (% of NOA). Net operating assets flipped from positive to negative FY2024→FY2025 (FY2024 $+4.2M to FY2025 $-1.8M) — the standard accruals ratio divides by the average of the two, which collapses toward zero right as the sign changes, so the resulting percentage is a denominator artifact, not a real accrual measurement. Treat this as a structural balance-sheet shift to understand on its own terms rather than a clean or dirty accruals read.

11096% of rev

FY2025

Stock-based comp load. Stock-based compensation ran 11096% of revenue in FY2025 — about $0.07 per diluted share. The cost of it is not in the cash flow — no cash left the business — it is in the count, and there it has run at about 20.3% a year, small enough that totals and per-share results tell the same story.

Key fundamentals

Latest Revenue$21,796.00

Net Margin-39662.8%

The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Jupiter Neurosciences, Inc.'s actual 10-K/10-Q/8-K filings?

Generate the AI investment read →

No credit card · informational only, not investment advice · see the track record

← Browse all forensic stock analyses

Data from SEC EDGAR public filings · metrics as of Aug 11, 2026. Forensic signals flag probability, not certainty.